Immune globulin - OMRIX Viopharmaceuticals

Drug Profile

Immune globulin - OMRIX Viopharmaceuticals

Alternative Names: Immune deficiency immune globulin therapy - Omrix; Immunoglobulin intravenous - Omrix; Intravenous immunoglobulin - Omrix; Omr-IgG-am; Omr-IgG-am™-IVIG

Latest Information Update: 31 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OMRIX Biopharmaceuticals
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Autoimmune disorders; Immunodeficiency disorders

Most Recent Events

  • 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson
  • 28 Sep 2006 IVIG has been licensed to FFF enterprises in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top